Company dispensed over 1,000 FDA-cleared systems in pilot phase; unveils new website and second-generation device for early 2026 launch LOS ANGELES, Nov. 18, 2025 (GLOBE NEWSWIRE) -- NeuroSigma, Inc. , a Los Angeles-based bioelectronics company, today announced the successful completion of its pilot commercialization program for the first-generation Monarch eTNS ®  System and the launch of a new website in preparation for release of its second-generation Monarch device. The pilot program...

Peer-reviewed results of PET neuroimaging demonstrate rapid and profound changes to humans receiving eTNS LOS ANGELES, Nov. 03, 2025 (GLOBE NEWSWIRE) -- NeuroSigma, Inc. , a Los Angeles-based bioelectronics company, today announced a new publication in the journal Neuromodulation: Technology at the Neural Interface.  The publication, titled "Oxygen-15 Labeled Positron Emission Tomography During External Trigeminal Nerve Stimulation ," is the first-ever to report the real-time effects on...

THIO-101 Phase 2 trial to enroll patients in the U.S. as part of the expansion of the study in third-line treatment for advanced...